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Osterix (Osx) is an essential regulator for osteoblast differentiation and bone formation. Although
phosphorylation has been reported to be involved in the regulation of Osx activity, the precise
underlying mechanisms remain to be elucidated. Here we identiﬁed S422 as a novel phosphoryla-
tion site of Osx and demonstrated that GSK-3b interacted and co-localized with Osx. GSK-3b
increased the stability and transactivation activity of Osx through phosphorylation of the newly
identiﬁed site. These ﬁndings expanded our understanding of the mechanisms of posttranslational
regulation of Osx and the role of GSK-3b in the control of Osx transactivation activity.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bone is a dynamic tissue that is constantly being reshaped by
bone-forming osteoblasts and bone-resorbing osteoclasts. The dif-
ferentiation of osteoblasts from mesenchymal progenitors requires
the activity of speciﬁc transcription factors (such as Runx2 and
Osterix) and developmental signals (including BMPs, Wnt ligands,
hormones, growth factors and cytokines) for induction of osteoge-
nesis [1]. Among which, the speciﬁc transcription factors are
expressed and function at distinct time points during the differen-
tiation process, thereby deﬁning various developmental stages of
the osteoblast lineage [2].Osterix (Osx/sp7), a transcription factor crucial for osteoblast
and osteocyte differentiation and functions, was discovered as a
BMP-induced gene in C2C12 cells [3]. Osx plays an essential role
in regulating the differentiation of preosteoblasts into mature
osteoblasts in a step downstream of Runx2. Deletion of Osx result-
ed in complete absence of osteoblasts in mouse embryos [3,4].
Post-translational modiﬁcations (PTMs) play a great role of
decorating proteins and driving their fate in cells by affecting
multiple parameters including stability and localization [5].
Dysregulation of PTMs or mutation of modiﬁed residues are linked
to disease, including cancer, Alzheimer and cardiovascular disease,
highlighting the importance of these protein modiﬁcations [6–8].
Phosphorylation is the most common PTMs. Adding or removing
a dianionic phosphate group somewhere on a protein often
changes the protein’s structural properties, its stability and
dynamics [9]. Studies have shown that phosphorylation of Osx
mediated by GSK-3a and Akt enhances the osteogenic activity of
Osx [10,11], while p38-mediated phosphorylation of Osx at
Ser-73/77 enhances the recruitment of coactivators to form tran-
scriptionally active complexes [12]. Despite the accumulated
knowledge of the phosphorylational modiﬁcation of Osx,
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the differential regulation of Osx remain to be explored.
Glycogen synthase kinase-3 (GSK-3) was originally identiﬁed
as a Serine/Threonine kinase involved in the regulation of glyco-
gen deposition and later functions as the key regulator of Wnt
and PI3 kinase/Akt signaling [13,14]. In mammals, GSK-3 con-
sists of two isoforms, GSK-3a and GSK-3b. GSK-3a and GSK-3b
are not functionally identical, although structurally similar
[15,16]. GSK-3b phosphorylates a number of substrates which
are involved in embryonic development, protein synthesis, mito-
sis, and survival [13,17–19]. Whether GSK-3b is involved in the
regulation of Osx and inﬂuences its function is not known to
date.
In the present study, we identiﬁed S422, which was conserved,
as a novel phosphorylation site of Osx by combining bioinformatics
analysis, mass spectrometric analysis and site directed mutage-
nesis. Moreover, we demonstrated that GSK-3b interacted and
co-localized with Osx. Our data also showed that GSK-3b increased
the stability and transactivation activity of Osx through mediating
the modiﬁcation of the newly identiﬁed phosphorylation site.
These results expanded our understanding of the mechanisms of
posttranslational regulation of Osx and the role of GSK-3b in the
control of Osx transactivation activity.2. Materials and methods
2.1. Cell, regents and antibodies
HEK 293T and MC3T3-E1 cells were maintained in high glucose
Dulbercco’s modiﬁed Eagle’s medium (DMEM) and a-minimal
essential medium (a-MEM), respectively. The media were supple-
mented with 10% fetal bovine serum (FBS), 100 units/ml penicillin
and 100 lg/ml streptomycin. All cells were cultured at 37 C in a
humidiﬁed atmosphere containing 5% CO2. Lipofectamine 2000
and Alexa Fluor 594 antibodies were purchased from Invitrogen
(Carlsbad, CA, USA). Lithium chloride (LiCl) was purchased from
Xilong Chemical (Guangdong, China). Protein-G agarose beads
and PVDF membrane were obtained from Millipore (Bedford, MA,
USA). Cycloheximide (CHX) and MG-132 were purchased from
Sigma (St. Louis, MO, USA). Protease inhibitors and FastStart
Universal SYBR Green Master (Rox) were purchased from Roche
(Indianapolis, IN, USA). RNAiso plus and PrimeScript RT reagent
kit were purchased from TaKaRa Biotechnology (Dalian, China).
ECL reagent was obtained from Pierce (Rockford, IL, USA). HA-
tagged GSK-3b expression plasmid was obtained from Addgene
(Cambridge, MA, USA). Rabbit anti-Osx antibody was obtained
from Abcam (Cambridge, MA, USA). Mouse anti-Flag antibody
and anti-HA antibody were obtained from Sigma. Mouse anti-
b-actin antibody, anti-rabbit and anti-mouse IgG antibody were
obtained from Santa Cruz (Santa Cruz, CA, USA).2.2. Plasmid construction and mutagenesis
Osx cDNA was inserted into pRKI vector at the EcoR I and Hind
III sites to generate wide type pRKI-Flag-Osx plasmid (WT-Osx).
WT-Osx was used as a template to generate the phosphorylation
site mutant constructs using PCR-driven overlap extension. cDNA
of WT-Osx and S422R-Osx was ampliﬁed and subsequently sub-
cloned into pRKI-GFP vector at the EcoR I and Bam HI sites to gen-
erate GFP-Osx or GFP-S422R-Osx fusion constructs. HA-tagged
GSK-3a expression plasmid was constructed by inserting the
GSK-3a cDNA into EcoR I and Bam HI sites of the pRK2H vector.
The inserted fragments were conﬁrmed by sequencing. GSK-3b
expression plasmid was obtained from Addgene (Cambridge, MA,
USA). hOc-Luc reporter plasmid and b-gal expression plasmid weredescribed previously [20]. The primer sequences used in the plas-
mid construction were shown in the Supplementary material.
2.3. LC–MS/MS assays of phosphorylation sites
HEK 293T cells transfected with Flag-tagged Osx expression
plasmid were lysed with radioimmunoprecipitation assay (RIPA)
lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, and 0.1% SDS) containing protease
and phosphatase inhibitors. Osx was immunopuriﬁed from the cell
lysates with anti-Flag antibody before being resolved by 8% PAGE.
After silver staining, the protein band corresponding to the
molecular weight of Osx was excised and subjected to liquid chro-
matography with tandem mass spectrometry (LC–MS/MS)
analysis.
2.4. Western blot
Western blot was performed as previously descripted [20].
Brieﬂy, cells were lysed with RIPA buffer plus protease inhibitors,
separated via SDS–PAGE, transferred to PVDF membrane,
immunoblotted, and detected with ECL reagent.
2.5. Co-immunoprecipitation (Co-IP) assay
HEK 293T cells co-transfected with HA-tagged GSK-3b and Flag-
tagged WT-Osx or S422R-Osx expression plasmids were lysed with
RIPA buffer plus protease and phosphatase inhibitors. 400 ll of the
cell lysates were incubated overnight at 4 C with anti-HA anti-
body. To precipitate the immunocomplexes, 50 ll of protein-G
agarose beads were added and incubated at 4 C for 6 h. The agar-
ose beads were pelleted by centrifugation and then washed with
RIPA buffer. The agarose slurry was collected by centrifugation
and precipitated proteins were detected by Western blot as above.
2.6. Immunoﬂuorescence staining
HEK 293T cells were plated onto the six-well plate with glass
bottom inserts. The cells were co-transfected with HA-tagged
GSK-3b and GFP-Osx or GFP-S422R-Osx fusion constructs. 30 h
after transfection, the cells were ﬁxed in 4% paraformaldehyde
for 20 min at room temperature (RT). After washing twice with
PBS, cells were permeabilized with PBS containing 0.5% Triton
X-100 for 10 min at 4 C, then treated with blocking buffer contain-
ing 4% bovine serum albumin (BSA) for 45 min at RT. The cells were
incubated with anti-HA (1:1000) antibody overnight at 4 C,
followed by incubation with Alexa Fluor 594 antibodies (1:200)
for 1 h at RT. Cells were then mounted in Vectashield containing
DAPI. Confocal images were taken on a Zeiss LSM710-NLO meta.
2.7. Luciferase reporter assay
HEK 293T cells were co-transfected with the hOc-Luc reporter,
b-gal construct, HA-tagged GSK-3b, Flag-tagged WT-Osx or
S422R-Osx expression plasmids. 36 h after transfection, the cells
were treated with or without LiCl. 24 h after treatment, luciferase
activity was measured with the Luciferase Reporter System
(Promega) using a GloMax™ Base Instrument. Relative luciferase
activity was calculated by normalizing to the corresponding b-gal
activity for transfection efﬁciency.
2.8. RNA isolation and Real-time PCR
RNAiso plus was used for total RNA isolation from cultured cells
according to the manufacturer’s protocol. The ribosomal bands
were visualized on a 1% TAE agarose gel to assess RNA integrity.
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tion reactions with the PrimeScript RT reagent kit and the Real-
time PCR was performed with FastStart Universal SYBR Green
Master (Rox) using a Roche LightCycler 96 Real-Time PCR
System. The ampliﬁcation conditions were 95 C for 10 min,
followed by 40 ampliﬁcation cycles of 95 C for 10 s and 60 C for
30 s. Expression values were normalized to b-actin. Primers used
for ampliﬁcation were listed in the Supplemental material.
2.9. Statistical analyses
Results are expressed as mean ± S.D. The Student’s t-test and
analysis of variance (ANOVA) were used to assess differences;
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Prediction and preliminary validation of phosphorylation sites of
Osx
To identify other phosphorylation sites of Osx except for
serine 76 and serine 80 [10], we performed bioinformatics analysis
ﬁrstly. Fig. 1A showed the potential phosphorylation sites of
Osx predicted by using phosphorylation site prediction tool
Musite (http://musite.net/), among which S422 was predicted with
a higher score. Since phosphorylation may trigger the transitions
between conformations with different activity and/or binding
speciﬁcity leading to activation or deactivation of a protein
[9,21,22], we constructed mutant Osx plasmids with the substitu-
tion of serine, tyrosine, threonine residues by phenylalanine or
arginine or alanine residues to examine the effects of the predictedFig. 1. Prediction and preliminary validation of phosphorylation sites of Osx. (A) Amino
(B) Flag-tagged WT-Osx and the mutant Osx constructs indicated were transiently trans
Actin was used as a loading control. (C) hOc-Luc reporter, b-gal expression plasmid, and
cells. Relative luciferase activity was measured 36 h after transfection and normalized
performed in triplicate. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.phosphorylation sites on the transactivation activity of Osx. Fig. 1B
showed the expression of the mutant constructs. Then the hOc-Luc
construct containing the Osx binding site was co-transfected with
the WT-Osx or mutant Osx expression plasmids into the Osx-deﬁ-
cient HEK 293T cells. As shown in Fig. 1C, the luciferase activities
were signiﬁcantly decreased in the S31A, Y48F, Y229F, T405A,
T414R and S422R mutant transfection in comparison with that of
the WT-Osx transfection, suggesting that these residues may be
phosphorylation sites.
3.2. Serine 422 is identiﬁed as a novel phosphorylation site of Osx by
mass spectrometry analysis
To conﬁrm the phosphorylation site(s) of Osx further, we con-
ducted mass spectrometry analysis using Osx protein immunopre-
cipitated with anti-Flag antibody from HEK 293T cells transiently
transfected with Flag-tagged Osx expression plasmids. S422 was
identiﬁed as a novel and sole phosphorylation site of Osx
(Fig. 2A). Further analysis revealed that S422 is located at the C
terminal of Osx (Fig. 2B), and it is a conserved amino acid among
various species (Fig. 2C).
3.3. GSK-3b is involved in the Osx phosphorylation at S422
To determine which kinase is involved in the phosphorylation
of Osx at S422, we runned the NetPhosK 1.0 Server and Group-
based Prediction System to predict the putative kinases. GSK-3b
was predicted to be involved in the phosphorylation of peptide
PEKAPGGS(422)PEQSNLL. To conﬁrm this, we transfected Flag-
tagged Osx expression plasmids into HEK 293T cells and then
treated with GSK-3 inhibitor, LiCl. As shown in Fig. 3A, treatmentacid sequence and the predicted phosphorylation sites of human Osx using Musite.
fected into HEK 293T cells. The cell lysates were blotted with anti-Flag antibody. b-
the WT-Osx plasmid or mutant Osx constructs were co-transfected into HEK 293T
to the b-gal activity. Results are mean ± S.D. of three independent experiments
Fig. 2. Identiﬁcation of phosphorylation sites of Osx by mass spectrometric analysis. (A) Cell lysates from HEK 293T cells transfected with Flag-tagged WT-Osx expression
plasmid were immunoprecipitated with an anti-Flag antibody. The eluate was resolved by gel electrophoresis, and the band containing Osx was excised and in-gel digested
with trypsin for liquid chromatography-tandem mass spectrometry (LC MS/MS) analysis. The tandem mass spectrometry spectrum from the peptide containing Osx
phosporylated on S422 is shown. (B) A schematic diagram of Osx showing domains and the location of S422 on Osx. (C) Alignment of C-terminal amino acid sequence of Osx.
Highlighted amino acid indicates the phosphorylated residue identiﬁed and the conservation of this residue between various species.
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decrease was in a dose-dependent manner, suggesting that GSK-
3 may participate in the regulation of Osx expression. GSK-3 com-
prised of two isoforms: GSK-3a and GSK-3b. Of which, GSK-3a has
been demonstrated to interact with Osx [10]. To determine
whether there exists an interaction between GSK-3b and Osx, wetransiently co-transfected HA-tagged GSK-3b with Flag-tagged
WT-Osx or S422R-Osx expression plasmids into HEK 293T cells.
Cell lysates were immunoprecipitated with an anti-HA antibody
and immunoblotted with an anti-Flag antibody. As shown in
Fig. 3B, GSK-3b interacted with both WT-Osx and S422R-Osx.
Next we examined whether GSK-3b was co-localized with
Fig. 3. GSK-3b is involved in Osx phosphorylation at S422. (A) Flag-tagged WT-Osx expression plasmid was transiently transfected into HEK 293T cells. 24 h after
transfection, the cells were treated with GSK-3 inhibitor LiCl in the indicated dose for 12 h. Osx was detected by immunoblotting analysis with anti-Flag antibody. b-Actin was
used as a loading control. (B) HEK 293T cells were transiently co-transfected with HA-tagged GSK-3b and Flag-tagged WT-Osx or S422R-Osx expression plasmids. The cell
lysates were immunoprecipitated with an anti-HA antibody, and then blotted with an anti-Flag antibody. (C) HEK 293T cells were co-transfected with HA-tagged GSK-3b and
WT-Osx-GFP or S422R-Osx-GFP expression plasmids. 30 h after transfection, cells were ﬁxed and incubated with anti-HA antibody, Alexa Fluor 594 antibodies. The images
were captured and visualized under confocal laser scanning microscope.
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was co-transfected with GFP-taggedWT-Osx or S422R-Osx expres-
sion plasmids into HEK 293T cells. After 30 h of transfection, cells
were ﬁxed, permeabilized, and incubated with anti-HA and Alexa
Fluor 594 antibodies sequentially. As shown in Fig. 3C, both WT-
Osx and S422R-Osx were co-localized with GSK-3b in the nucleus.
These results indicate that GSK-3b may be involved in the phos-
phorylation modiﬁcation of Osx.
3.4. GSK-3b increases the protein stability and transactivation activity
of Osx
To examine the effects of GSK-3b on the stability of Osx, we
transfected Flag-tagged WT-Osx or S422R-Osx alone or together
with HA-tagged GSK-3b expression plasmids into HEK 293T cells.
24 h after transfection, cells were treated with cycloheximide
(CHX), an inhibitor of protein biosynthesis. As reported before,
WT-Osx is an unstable protein with a half-life of about 12 h
(Fig. 4A). The degradation of S422R-Osx was accelerated compared
to WT-Osx with a half-life of about 8 h (Fig. 4A). However, the
degradation of WT-Osx, especially the phosphorylated Osx (the
upper band), was obviously delayed by GSK-3b co-transfection
and this response was weakened in the S422R-Osx and GSK-3b
co-transfection (Fig. 4A). Meanwhile, we detected the effects ofGSK-3a on the stability of WT-Osx and S422R-Osx. We found that
the degradation of both WT-Osx and S422R-Osx was delayed by
GSK-3a co-transfection (Supplemental Fig. 1).
To explore the mechanisms by which S422 phosphorylation
increases the protein stability of Osx, we treated HEK 293T cells
transfected with WT-Osx or S422R-Osx expression plasmid with
proteasome inhibitor MG-132. As shown in Fig. 4B, MG-132 can
block the degradation of both WT-Osx and S422R-Osx, suggest-
ing that S422 phosphorylation may inhibit Osx degradation
mediated by proteasome pathway, thus increases Osx protein
stability.
To examine the effects of GSK-3b on the transactivation activity
of Osx further, we performed luciferase report assay and Real-time
PCR analysis. Results of luciferase reporter assays showed that the
transactivation activity of Osx was markedly enhanced by GSK-3b
and this enhancement was impaired by LiCl treatment (Fig. 4C).
The transactivation activity of S422R-Osx was decreased compared
to WT-Osx and there was no obvious response of S422R-Osx to
GSK-3b co-transfection and LiCl treatment (Fig. 4C). We also
detected the effects of GSK-3a on the transactivation activity of
Osx and S422R-Osx and found that the transactivation activity of
Osx was markedly enhanced by GSK-3a and this enhancement
was impaired by LiCl treatment. However, unlike GSK-3b, GSK-
3a can upregulate the transactivation activity of S422R-Osx and
Fig. 4. GSK-3b increases the protein stability and transactivation activity of Osx. (A) HEK 293T cells were transiently transfected with Flag-taggedWT-Osx or S422R-Osx alone
or together with HA-tagged GSK-3b expression plasmids. 24 h after transfection, cells were treated with 80 lM cycloheximide (CHX) for the indicated time. The protein levels
of Osx and S422R-Osx were detected by immunoblotting analysis with an anti-Flag antibody (left). The protein levels of Osx in left panel were determined by densitometry
(right). The levels of Osx protein in CHX-untreated cells were set to 100%. b-Actin was used as loading control. (B) Flag-tagged WT-Osx or S422R-Osx expression plasmids
were transfected into HEK 293T cells. 24 h after transfection, the cells were treated with MG-132 (20 lM) for various periods of time. WT-Osx and S422R-Osx were detected
by Western blot analysis with an anti-Flag antibody. b-Actin was used as loading control. The protein levels of Osx in left panel were determined by densitometry (right). (C)
hOc-Luc reporter, b-gal, GSK-3b, together with WT-Osx or S422R-Osx expression plasmids were transfected into HEK 293T cells. 36 h after transfection, cells were treated
with LiCl (100 mM) or not. Relative luciferase activity was measured 24 h after treatment and normalized to the b-gal activity. Results are mean ± S.D. of three independent
experiments performed in triplicate. (D) MC3T3-E1 cells were transfected with Flag-tagged WT-Osx or S422R-Osx alone or together with HA-tagged GSK-3b expression
plasmids. 48 h after transfection, the mRNA levels of Osx target genes including ALP, OC and BSP were detected by Real-time PCR. b-Actin was used as an internal control.
Results are mean ± S.D. of three independent experiments performed in triplicate; ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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Fig. 2).
In addition, the mRNA expression of Osx target genes including
alkaline phosphatase (ALP), osteocalcin (OC) and bone sialoprotein
(BSP) induced by S422R-Osx was signiﬁcantly decreased compared
to that induced by WT-Osx.
Furthermore, GSK-3b co-transfection signiﬁcantly increased
Osx target gene expression in comparison with Osx transfection
alone, whereas this increase was not seen in the GSK-3b and
S422R-Osx co-transfection (Fig. 4D). Together, these results sug-
gest that GSK-3b increases the stability and transactivation activity
of Osx through mediating the phosphorylation of Osx at S422.
4. Discussion
Protein function is affected by its expression level, localization,
interaction with other proteins, and its posttranslational modiﬁca-
tions [23]. As a key regulator of osteoblast differential and bone
formation, the expression and activity of Osx have been reported
to be regulated at the posttranslational level. p38, Akt1, Erk1/2
and GSK-3a modulate the expression or activity of Osx through
phosphorylation modiﬁcation [10–12,24,25]. In the present study,
we identiﬁed S422 as a novel phosphorylation site of Osx.
Moreover, we found that GSK-3b interacted and co-localized withOsx. GSK-3b increased the stability and transactivation activity of
Osx through mediating the phosphorylation of Osx at S422.
The mass spectrometric strategy has been widely recognized as
a powerful and preferred approach for research in protein
phosphorylation [26,27]. To improve the detection sensitivity of
phosphorylation modiﬁcation identiﬁcations, enrichment of phos-
phopeptides is usually performed prior to mass spectrometric ana-
lysis [28–30]. In our study, enrichment of phosphopeptides prior to
mass spectrometric analysis was not performed. Moreover, an
external stimulus to increase the phosphorylation level of Osx
was not undertaken. These may be the reason why we identiﬁed
only one phosphorylation site in the mass spectrometric analysis.
Indeed, a single phosphorylation site may have dramatic effects
in regulating protein functions [31]. Although mass spectrometry
provides a reliable method to identify protein phosphorylation
sites, the experimental approach for identifying phosphorylation
events are costly, time-consuming, resource-dependent, and
biased toward abundant proteins and proteotypic peptides
[32,33]. Computational prediction provides an efﬁcient and ﬂexible
way to reveal potential phosphorylation sites and provide
hypotheses in experimental design [33]. While using computation-
al prediction, any particular cellular conditions were not consid-
ered. We predicted twelve potential phosphorylation sites of Osx
using Musite and six of them were preliminarily demonstrated
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analysis. We speculate that the remainder of the predicted sites of
Osx may be phosphorylated under speciﬁc cellular conditions.
Mammalian GSK-3 consists of two isoforms, GSK-3a (molecular
mass 51 kDa) and GSK-3b (molecular mass 47 kDa). Although the
catalytic domains of GSK-3a and GSK-3b exhibit 97% sequence
homology [14,34], they might have distinct physiological functions
[35]. GSK-3b is a multifunctional kinase which phosphorylates a
number of substrates involved in embryonic development, protein
synthesis, mitosis, and survival [13,17–19]. It has been reported
that GSK-3a phosphorylates Osx at S76 and S80 and up-regulates
the osteogenic activity of Osx [10]. Here, we found that GSK-3b
interacted and co-localized with Osx too, implying it may play a
role in the functional regulation of Osx through phosphorylation
modiﬁcation.
Phosphorylation is the most common and pleiotropic
modiﬁcation in biology, which plays a vital role in regulating
and ﬁnely tuning a multitude of biological pathways [36,37].
Phosphorylation can either activate or inactivate a protein
through triggering the transitions between conformations with
different activity and/or binding speciﬁcity [9,21,22]. In this
study, we found that Osx protein stability was enhanced by
GSK-3b. In addition, MG-132 can block the degradation of both
WT-Osx and S422R-Osx. These data suggest that S422 phosphory-
lation may inhibit Osx degradation mediated by proteasome
pathway, thus increases Osx protein stability. Unfortunately, no
E3-ligase involved in the ubiquitin–proteasome degradation of
Osx has been identiﬁed till now. We speculate that the phospho-
rylation of Osx at S422 may alter the conformation of Osx,
thereby disturb the interactions between Osx and the E3-ligase
and inhibits the degradation of Osx. Additionally, Co-IP assays
showed that S422R-Osx interacted with GSK-3b still, indicating
that S422 is not the residue responsible for the interaction
between GSK-3b and Osx.
In summary, we have revealed S422 as a novel phosphorylation
site of Osx and GSK-3b played an important role in regulating the
protein stability and transactivational activity of Osx. Although it
remains to be explored the roles of Osx phosphorylation at S422
in osteoblast differentiation and bone formation, our results sug-
gest that S422 of Osx may be constitutively phosphorylated at
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